2004 Access Safety Treatment 
Cannabis Law Report
DECEMBER 1, 2021
Ethics, Safety, and Abuse in Psychedelic Medicine. As psychedelic medicine becomes more mainstream, we must ensure that all who participate in healing therapeutic sessions, both above ground and in ceremonial or underground therapeutic settings, are safe and accessible to all. Wednesday, December 8th from 12:00-2:00pm PST.
Cannabis Law Report
OCTOBER 29, 2019
ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., Dr. Wakshlag is currently available for interviews to discuss the results of the safety study as well as his clinical trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
NOVEMBER 30, 2021
Veriheal does not support illegally consuming therapeutic substances such as psilocybin but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. In 2008, he published psychedelic safety guidelines.
Cannabis Law Report
MAY 28, 2019
Veterans Struggle to Gain Access to Medical Marijuana. Despite this expansion military veterans often face greater obstacles to gaining access to medical marijuana than other groups. VHA treatment may require blood testing and urinalysis which can reveal marijuana use. 2004), United States v. May 2, 2019. United States v.
Veriheal
OCTOBER 1, 2020
In 2004, cannabis was reclassified as a class C drug but was reinstated to Class B in 2008 following Prime Minister Gordon Brown’s decision to go against the advice offered up by the Advisory Council on the Misuse of Drugs. . Cannabis is easily accessible, and the regulations are loosening up quite a bit.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.
The Cannigma
JANUARY 13, 2023
4 A 2004 study found that the endocannabinoid anandamide can inhibit trigeminal neurons, which suggests a way in which endocannabinoids may be able to prevent migraines. Daily cannabis consumption was an effective treatment for 85% of participants. 5 THC and migraines THC is well-known for its anti-nausea and pain-relieving effects.
Expert insights. Personalized for you.
52 
Let's personalize your content